CNS Metastases in Patients With MET Exon 14–Altered Lung Cancers and Outcomes With Crizotinib

PURPOSE: Although MET exon 14 (METex14)–altered lung cancers were first identified more than a decade and a half ago, the frequency of CNS metastatic disease remains poorly defined. Furthermore, the seminal trial of crizotinib in these patients (PROFILE 1001) did not report patterns of CNS response...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:JCO Precis Oncol
Egile Nagusiak: Offin, Michael, Luo, Jia, Guo, Robin, Lyo, John K., Falcon, Christina, Dienstag, Jordan, Wilkins, Olivia, Chang, Jason, Rudin, Charles M., Riely, Gregory, Rekhtman, Natasha, Arcila, Maria E., Heller, Glenn, Ladanyi, Marc, Li, Bob T., Kris, Mark G., Paik, Paul, Drilon, Alexander
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2020
Gaiak:
Original Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446485/
https://ncbi.nlm.nih.gov/pubmed/32923895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.20.00098
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak